Asymmetric Total Synthesis of a Beer-Aroma Constituent Based on Enantioconvergent Biocatalytic Hydrolysis of Trisubstituted Epoxides

Andreas Steinreiber, Sandra F. Mayer, Kurt Faber*

Department of Chemistry, Organic and Bio-organic Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria Fax +43(316)3809840; E-mail: Kurt.Faber@KFUNIGRAZ.AC.AT

Received 11 June 2001; revised 27 July 2001

Abstract: A short asymmetric total synthesis of the plant constituent myrcenediol [(*R*)-1], and (*S*)-7,7-dimethyl-6,8-dioxabicyc-lo[3.2.1]octane (2), which is a volatile constituent of the aroma of beer was accomplished via a chemoenzymatic protocol. The key step consisted of a biocatalytic hydrolysis of trisubstituted epoxides bearing olefinic side chains which proceeded in an enantioconvergent fashion, i.e., a single enantiomeric *vic*-diol was obtained from the racemate in up to 91% ee and 92% isolated yield.

Key words: epoxide hydrolase, enantioconvergent hydrolysis, trisubstituted epoxide, beer-aroma

Bacterial epoxide hydrolases have been shown to be highly versatile biocatalysts for the preparation of nonracemic vic-diols. In particular, sterically more demanding 2,2disubstituted epoxides were hydrolyzed with excellent selectivities (E-values up to >200)¹ and for 2,3-disubstituted analogues, the biohydrolysis was shown to proceed in an enantioconvergent fashion, i.e., only a single stereoisomeric vic-diol was formed from the rac-epoxide in 100% theoretical yield.² Most recently, this phenomenon of enantio-convergence was also observed for trialkyl-oxiranes.³ In order to apply this highly efficient method for the generation of nonracemic vic-diols to natural product synthesis, we investigated trisubstituted epoxides bearing olefinic side chains, which would serve as functional groups for further (oxidative) transformations. From our previous studies^{4,5} it was anticipated that these lipophilic substrates would be well accepted by epoxide hydrolases. In this context, epoxides possessing a terpenoid structural framework seemed to be an attractive synthetic target.

Myrcenediol (1) is a plant constituent, which was isolated from the roots of *Bidens graveolens*⁶ and from the flowers of *Tanacetum annuum*.⁷ Neither its enantiomeric excess nor its absolute configuration was investigated. The (*R*)enantiomer of 1, which was synthesized via four steps from myrcene (4a) using Baker's yeast reduction of a ketone for the introduction of chirality, served as chiral building block for the synthesis of Hippospongic Acid A.⁸

The (*S*)-enantiomer of 7,7-dimethyl-6,8-dioxabicyclo[3.2.1]octane (**2**) is known as a volatile contributor to the aroma of beer⁹ and was first isolated from Japanese hop oil.¹⁰ Asymmetric synthesis of **2** was accomplished using tartaric acid as chiral starting material,¹¹ through resolution,¹² or via asymmetric cycloaddition employing Oppolzer's chiral sultam¹³ and Sharpless dihydroxylation.¹⁴ Retrosynthetic analysis showed that both of the target compounds are easily accessible via an enantioconvergent biocatalytic hydrolysis of trisubstituted epoxides bearing suitable olefinic side chains as the key step (Scheme 1).



Scheme 1 Retrosynthetic analysis

Epoxides *rac*-4 and *rac*-5 were prepared from commercially available alkenes 4a and 5a via chemoselective epoxidation of the electron-rich internal C=C bond using *m*chloroperbenzoic acid in 83% yield (Scheme 2). The absence of spontaneous hydrolysis in aqueous buffer was verified for both substrates in the absence of biocatalyst and was shown to be negligible (<3%) within the anticipated reaction time of ~48 hours.

In order to find a suitable biocatalyst, *rac*-4 and *rac*-5 were screened for hydrolytic activity using resting cells of a range of pigment-producing bacteria which are known to possess epoxide hydrolase activity (Table 1). In each case, where activity was observed, the corresponding diol 1 or 6, respectively, was the only detectable product.



Scheme 2 Synthesis of substrates and biocatalytic hydrolysis

Table 1 shows the stereoselectivities [given as conversion (c) and enantiomeric purities of substrate (ee_s) and product (ee_p)]¹⁵ obtained in the biohydrolysis of *rac*-4 and *rac*-5. Substrate 4 was hydrolyzed with low to acceptable selectivities by several strains with the predominant forma-

Synthesis 2001, No. 13, 08 10 2001. Article Identifier: 1437-210X,E;2001,0,13,2035,2039,ftx,en;Z06401SS.pdf. © Georg Thieme Verlag Stuttgart · New York ISSN 0039-7881

Table 1 Stereoselectivities from the Biocatalytic Hydrolysis of rac-4 and rac-5

	Substrate						
Entry		4			5		
Strain	Conversion ^a (%)	ee Epoxide	ee Diol	Conversion ^b (%)	ee Epoxide	ee Diol	
Rhodococcus ruber DSM 44540	64	86 (<i>R</i>)	86 (<i>R</i>)	80	75 (<i>S</i>)	82 (<i>R</i>)	
Rhodococcus ruber DSM 44539	46	85 (<i>R</i>)	60 (<i>R</i>)	82	64 (<i>S</i>)	82 (<i>R</i>)	
Rhodococcus ruber DSM 44541	65	87 (<i>R</i>)	85 (<i>R</i>)	78	59 (<i>S</i>)	77 (<i>R</i>)	
Rhodococcus equi IFO 3730	73	9 (<i>R</i>)	85 (<i>R</i>)	64	7 (<i>R</i>)	50 (R)	
Rhodococcus sp. CBS 717.73	54	78 (<i>R</i>)	40 (<i>S</i>)	71	8 (<i>S</i>)	60(R)	
Mycobacterium paraffinicum NCIMB 10420	29	83 (<i>R</i>)	34 (<i>R</i>)	71	> 99 (R)	81 (<i>R</i>)	
Arthobacter sp. DSM 312	10	7 (<i>S</i>)	14 (<i>R</i>)	4	3 (<i>R</i>)	44 (S)	
Streptomyces lavendulae ATCC 55209	2	<1	22 (<i>R</i>)	6	5 (<i>R</i>)	96 (R)	
	Strain Rhodococcus ruber DSM 44540 Rhodococcus ruber DSM 44539 Rhodococcus ruber DSM 44541 Rhodococcus equi IFO 3730 Rhodococcus sp. CBS 717.73 Mycobacterium paraffinicum NCIMB 10420 Arthobacter sp. DSM 312 Streptomyces lavendulae ATCC 55209	Substrate4StrainConversiona (%)Rhodococcus ruber DSM 4454064Rhodococcus ruber DSM 4453946Rhodococcus ruber DSM 4454165Rhodococcus sp. CBS 717.7373Rhodococcus sp. CBS 717.7354Mycobacterium paraffinicum NCIMB 1042029Arthobacter sp. DSM 31210Streptomyces lavendulae ATCC 552092	Substrate4StrainConversiona (%)e Epoxide (%)Rhodococcus ruber DSM 445406486 (R)Rhodococcus ruber DSM 445394685 (R)Rhodococcus ruber DSM 445416587 (R)Rhodococcus squi IFO 3730739 (R)Rhodococcus sp. CBS 717.735478 (R)Mycobacterium paraffinicum NCIMB 104202983 (R)Arthobacter sp. DSM 312107 (S)Streptomyces lavendulae ATCC 552092	Substrate4StrainConversiona (%)ee Epoxide e e Diol (%)Rhodococcus ruber DSM 445406486 (R)Rhodococcus ruber DSM 445394685 (R)Rhodococcus ruber DSM 445416587 (R)Rhodococcus sp. CBS 717.73739 (R)Rhodococcus sp. CBS 717.735478 (R)Arthobacter sp. DSM 312107 (S)Streptomyces lavendulae ATCC 552092<1	Substrate45StrainConversion® (%)ee Epoxide (ee Diol)Conversion® (%)Rhodococcus ruber DSM 445406486 (R)86 (R)80Rhodococcus ruber DSM 445394685 (R)60 (R)82Rhodococcus ruber DSM 445416587 (R)85 (R)78Rhodococcus equi IFO 3730739 (R)85 (R)64Rhodococcus sp. CBS 717.735478 (R)40 (S)71Arthobacter sp. DSM 312107 (S)14 (R)4Streptomyces lavendulae ATCC 552092<1	Substrate45StrainConversion (%)er Diol (%)Conversion (%)er Diol (%)conversion 	

^aAfter 48 h.

^bAfter 40 h.

tion of (*R*)-1 in up to 86% ee, except for *Rhodococcus sp*. CBS 717.73, which produced the (*S*)-enantiomer (entry 5). Several data sets of c, e_s and e_p clearly indicated that the transformation does not follow a kinetic resolution pathway, which is most striking for entries 1, 3, 4 and 5.

Similar results were obtained for substrate *rac*-**5**. Again, the formation of (R)-**6** was predominant with a single exception (*Arthobacter sp.* DSM 312, entry 7). The clear indication of a non-kinetic-resolution-type was even more evident for substrate *rac*-**5**, in particular for entries 1–6 and the possibility of an enantioconvergent transformation - as indicated by a high ee_p at conversion far beyond the 50%-benchmark - is evident for entries 1–3.

The mechanistic reason for this enantioconvergent pathway is the fact that both enantiomers are hydrolyzed with opposite regioselectivity, whereas the (*S*)-enantiomer of the oxirane is attacked by $[OH^-]$ at the less substituted oxirane carbon atom with concomitant inversion of configuration, the (*R*)-enantiomer is transformed via retention through attack at the fully substituted oxirane carbon atom. Both pathways lead to the formation of an (*R*)-configurated diol from a *rac*-epoxide as the sole product.³

For preparative-scale biotransformations, *Rhodococcus ruber* DSM 44540 was chosen as the prime candidate, since it gave best selectivity for *rac*-4 and was proven to be suitable towards upscaling.¹⁶ Unfortunately, the most selective strain for substrate *rac*-5 (*Streptomyces laven-dulae* ATCC 55209) was hampered by insufficient reaction rates.

Thus, hydrolysis of *rac*-4 (50 mg) using 0.2 g of resting cells of *Rhodococcus ruber* DSM 44540 in Tris-buffer (pH 8.0) gave 52 mg of (R)-Myrcenediol (1) in 92% yield and 83% ee as the sole product. The absolute configuration of 1 was determined by comparison with indepen-

dently synthesized material.⁸ The overall yield from alkene 4a to (*R*)-1 was 68%.

In a similar fashion, (*R*)-2-methyl-7-octene-2,3-diol (**6**) was obtained from *rac*-**5** (211 mg) using 1.0 g of lyophilized *Rhodococcus ruber* DSM 44540 cells in 90% yield and 90% ee. The unexpected higher enantiomeric excess of the product at elevated conversion (compare entry 1) can be attributed to the assumption that the slower reacting (*S*)-enantiomer of the epoxide is transformed with higher regioselectivity than the (*R*)-counterpart.³ Oxidation of (*R*)-**6** by ozonolysis, followed by acid-catalyzed ring-closure in a one-pot reaction gave (*R*)-**2** in 80% yield and 95% ee (Scheme 3). The overall yield of the reaction sequence from alkene **5a** to (*R*)-**6** was 60%.



Scheme 3 Enantio-complementary chemoenzymatic synthesis of both enantiomers of bicyclic acetals 2 and 3

Since no bacterial strain produced (*S*)-**6** in high ee - which is required for the synthesis of the naturally occurring (*S*)enantiomer of **2** - the (*R*)-enantiomer was used as starting material instead. Inversion of the stereogenic center was achieved via an epoxide-closing-reopening sequence, which proceeded with inversion and retention of absolute configuration, respectively.^{17–19} Thus, diol (*R*)-**6** (ee 95%) was transformed into the corresponding trifluoromethane sulfonate²⁰ followed by immediate ring-closure in the presence of base (3 equivalents of pyridine) to give (*S*)-**5** in 94% yield and 95% ee. In order to effect a stereochemically 'clean' hydrolysis with complete retention of configuration under acidic conditions,^{17–21} the crude product had to be purified. Best results were achieved using a THF–H₂O mixture (1:1) and H₂SO₄ as catalyst. Thus 80 mg of (*S*)-**5** (ee 95%) gave 71 mg of (*S*)-**6** in 79% yield and 92% ee, which indicated that only a trace amount of racemization took place. The overall yield for the inversion sequence was 74%. Ozonolysis followed by acid-catalyzed acetal formation of (*S*)-**5** gave (*S*)-**2** in 77% yield and 92% ee.

In order to show the flexibility of the method, both enantiomers of the desmethyl-analogue (**3**) of the hop-oil ingredient were synthesized via Wacker oxidation of **6** using PdCl₂ as catalyst, and CuCl₂ as reoxidant. Thus 490 mg of (*R*)-**6** were transformed into 110 mg of (*R*)-**3** (ee 93%). Analogous results were obtained for the (*S*)-enantiomer.

In conclusion, we have demonstrated that the enantioconvergent hydrolysis of trisubstituted epoxides bearing olefinic side chains using bacterial epoxide hydrolases proceeded in a highly selective manner, which provided the corresponding *vic*-diols in almost quantitative yield. The latter compounds were transformed into terpenoid natural products in nonracemic form in a straightforward manner.

NMR spectra were recorded in CDCl₃ using a Bruker AMX 360 at 360 MHz (1H) and 90 MHz (13C), or a Bruker DMX Avance 500 at 500 MHz (1H) and 125 MHz (13C). Chemical shifts are reported relative to TMS ($\delta = 0.00$ ppm) with CHCl₃ as internal standard [$\delta =$ 7.23 (¹H) and 76.90 ppm (¹³C)], coupling constants (J) are given in Hz. ¹³C NMR multiplicities were determined by using a DEPT pulse sequence. TLC plates were run on silica gel Merck 60 (F_{254}) and compounds were visualized by spraying with vanillin/concd H₂SO₄ (5 g/L) (detection I), or by dipping into a KMnO₄ reagent $[2.5 \text{ g/L KMnO}_4 \text{ in } H_2\text{O}]$ (detection II). Compounds were purified either by flash chromatography on silica gel Merck 60 (230-400 mesh) or, for volatile compounds, by Kugelrohr distillation. Petroleum ether (PE) with boiling range of 60-90 °C was used. GC analyses were carried out on a Varian 3800 gas chromatograph equipped with FID and either a HP1301 or a HP1701 capillary column (both 30 m, 0.25 mm, 0.25 µm film, N₂). Enantiomeric purities were analyzed using a CP-Chirasil-DEX CB column (25 m, 0.32 mm, 0.25 μ m film) with H₂ as carrier gas. Solvents were dried and freshly distilled by common practice. For anhydrous reactions, flasks were dried at 150 °C and flushed with dry Ar just before use. Myrcene (4a, technical grade) and 7-methyl-1,6-octadiene (5a) were purchased from Aldrich. m-Chloroperbenzoic acid (70%, m-CPBA) from Fluka was used. Lyophilized bacterial cells were used for biotransformations. Bacteria were obtained from culture collections; the following strains (which were previously referred to the culture collection of the Institute of Biotechnology, Graz University of Technology), were classified and deposited at DSMZ (Braunschweig, Germany): Nocardia EH1 = Rhodococcus ruber SM 1789 = DSM 44540; Nocardia TB1 = Rhodococcus ruber SM 1790 = DSM 44539; Nocardia H8 = Rhodococcus ruber SM 1788 = DSM 44541; all strains were grown as previously described.22-25

Epoxidation of 4a and 5a to furnish 4 and 5; General Procedure Alkene **4a** or **5a** (35 mmol) was dissolved in CH_2Cl_2 (300 mL) and cooled to 0 °C. K₂CO₃ (9.5 g, 68.7 mmol) and *m*-CPBA (70%, 10.0 g, 40.6 mmol) were added and the suspension was stirred for 3 h. After the reaction was complete, solids were filtered and the filtrate was treated with Na₂S₂O₅ (10%, 200 mL). After phase separation, the organic phase was washed with sat. NaHCO₃ (3 × 200 mL), dried and evaporated. Kugelrohr distillation yielded pure epoxides **4** and **5**, details and spectroscopic data are given below.

6,7-Epoxy-7-methyl-3-methylene-1-octene

Epoxidation of **4a** (3.0 g, 24.0 mmol) yielded after Kugelrohr distillation (43 mbar, 115–120 °C) **4** (2.81 g, 83%) as a colorless liquid. R_f (PE–EtOAc, 1:1) = 0.85 (detection II).

 $^1\mathrm{H}$ NMR data were in full agreement with those previously reported. 26

¹³C NMR (90.55 MHz, CDCl₃): δ = 18.68, 24.76, 27.47, 28.30, 58.36, 63.98, 113.31, 116.03, 138.48, 145.34.

2,2-Dimethyl-3-pent-4-enyloxirane

Epoxidation of **5a** (2.0 g, 14.3 mmol) gave after Kugelrohr distillation (40 mbar, 125–30 °C) **5** (0.93 g, 83%) as a colorless liquid. R_f (PE–EtOAc, 1:1) = 0.78 (detection II); spectroscopic data were in full agreement with those previously reported.²⁷

2-Methyl-6-methylene-7-octene-2,3-diol [(R)-1]

Lyophilized cells of *Rhodococcus ruber* DSM 44540 (0.2 g) were rehydrated in Tris-buffer (15 mL, pH 8.0, 50 mM) for 1 h and *rac*-**4** (50 mg, 1.5 mmol) was added in one portion. The mixture was incubated at 30 °C for 200 h with shaking at 130 rpm. The solution was extracted thrice with CH₂Cl₂ (10 mL), dried (Na₂SO₄) and concentrated. After flash chromatography, (*R*)-**1** (52 mg, 92%, ee 83%) was isolated as a colorless oil. R_f (PE–EtOAc, 1:1) = 0.36 (detection II); spectroscopic data were in full agreement with those previously reported.²⁸

2-Methyl-7-octene-2,3-diol [(R)-6]

Lyophilized cells of *Rhodococcus ruber* DSM 44540 (1.0 g) were rehydrated in Tris-buffer (60 mL, pH 8.0, 50 mM) for 1 h and *rac*-**5** (211 mg, 1.5 mmol) was added in one portion. The mixture was incubated for 143 h at 30 °C. The solution was extracted 5 times with CH_2Cl_2 (40 mL), dried (Na_2SO_4) and concentrated. After flash chromatography (*R*)-**6** was isolated as a colorless oil (213 mg, 90%, ee 90%). R_f (PE–EtOAc, 1:1) = 0.32 (detection II); spectroscopic data were in full agreement with those previously reported.¹⁴

7,7-Dimethyl-6,8-dioxabicyclo[3.2.1]octane [(S)-2]

Diol (*S*)-**6** (30 mg, 0.19 mmol, ee 92%) was dissolved in anhyd CH₂Cl₂ (5 mL). The solution was cooled to -80 °C and O₃ was bubbled through until the blue color persisted. Excess O₃ was removed with a stream of Ar. PPh₃ (40 mg, 0.15 mmol) was added and the solution was allowed to warm to r.t. over 2 h. *p*-Toluenesulfonic acid (10 mg) was added and the solution was stirred overnight. The solution was washed with sat. NaHCO₃ (5 mL) and dried (Na₂SO₄). After concentration in vacuo at 0 °C, the crude product was purified by flash chromatography on silica gel (pentane–Et₂O, 95:5) to yield (*S*)-**2** (21 mg, 77%, ee 94%) as a colorless liquid. Spectroscopic data were in full agreement with those previously reported.¹³

$$[\alpha]_{D}^{20}$$
 –79.96 (*c* 0.50, CHCl₃).

 R_f (PE–EtOAc, 1:1) = 0.78, (detection I).

7,7-Dimethyl-6,8-dioxabicyclo[3.2.1]octane [(R)-2]

Diol (*R*)-6 (270 mg, 1.7 mmol, ee 91%) was treated with O₃, PPh₃ and *p*-toluenesulfonic acid as described above to yield (*R*)-2 (194 mg, 80%, ee 95%) as a colorless liquid. Spectroscopic data were identical to those of (*S*)-2.

 $[\alpha]^{D}_{20}$ +80.32 (*c* 0.64, CHCl₃).

5,7,7-Trimethyl-6,8-dioxabicyclo[3.2.1]octane [(R)-3]

Diol (*R*)-**6** (490 mg, 3.1 mmol, ee 91%) was dissolved in anhyd 1,2dimethoxyethane (10 mL). The solution was stirred at r.t., $PdCl_2$ (0.10 g, 0.56 mmol) and CuCl₂ (0.58 g, 4.3 mmol) were added and stirring was continued for 12 h. The brown solution was diluted with H₂O and Et₂O (10 mL each). After phase separation, the aqueous layer was extracted twice with Et₂O (5 mL). The combined organic phases were dried (Na₂SO₄) and concentrated. After flash chromatography (pentane–Et₂O, 10:1), (*R*)-**3** (110 mg, 23%, ee 93%) was isolated as a colorless liquid.

 R_f (PE-EtOAc, 1:1) = 0.84 (detection I).

¹H NMR (500.13 MHz, CDCl₃): δ = 1.29 (s, 3 H), 1.38 (s, 3 H), 1.43 (s, 3 H), 1.56–1.66 (m, 4 H), 1.89 (m, 2 H), 1.89 (s, 1 H).

¹³C NMR (125.76 MHz, CDCl₃): δ = 17.57, 21.35, 24.67, 26.27, 29.62, 34.61, 81.28, 81.56, 107.72.

5,7,7-Trimethyl-6,8-dioxabicyclo[3.2.1]octane [(S)-3]

Diol (*S*)-**6** (292mg, 1.8 mmol, ee 92%) was oxidized using the Wacker-oxidation procedure described above to yield (*S*)-**3** (71.4 mg, 25%, ee 96%). Spectroscopic data were identical to those of (*R*)-**3**.

Inversion Procedure for (*R*)-6 to (*S*)-6

Diol (*R*)-6 (180 mg, 1.1 mmol, ee 91%) was dissolved in anhyd CH₂Cl₂ (5 mL) under Ar and pyridine (0.25 mL, 3.12 mmol) was added. The solution was cooled to 0 °C and trifluoromethanesulfonic anhydride (0.23 mL, 1.37 mmol) was added. After 1 h the solution was washed with 5% HCl (5 mL) and sat. NaHCO₃ (5 mL). The organic phase was dried (Na₂SO₄) and concentrated. After flash chromatography (pentane–Et₂O, 5:1), (*S*)-5 (150 mg, 94%, ee 95%) was isolated as a colorless liquid. Epoxide (*S*)-5 (80 mg, 0.57 mmol) was added. The solution was stirred for 2 h and extracted twice with EtOAc (2 mL). The organic phase was washed with sat. NaHCO₃ (4 mL) and dried (Na₂SO₄). After flash chromatography (pentane–Et₂O, 2:1), (*S*)-6 was isolated as a colorless oil in 74% overall yield (71 mg, ee 92%). Spectroscopic data were in full agreement with those previously reported.¹⁴

Synthesis of Reference Material for rac-Diols 1 and 6

Diols (\pm)-1 and (\pm)-6 were obtained by acid-catalyzed hydrolysis of the corresponding *rac*-oxiranes 4 and 5 (0.2 M in H₂O–THF, 1:1 containing 3–4 drops of 6 N H₂SO₄). Extractive workup and flash chromatography (PE–EtOAc, 5:1) gave pure diols (\pm)-1 and (\pm)-6. Spectral data of these reference compounds matched those of material obtained from biotransformations and were in full agreement with those previously reported.¹⁴

Table 2	GC-Analyses	of Enantiom	eric Com	positions
---------	-------------	-------------	----------	-----------

Compound	Conditions	$t_{\rm R}$ (min) (Absolute Config.)
1	12 psi He, 135 °C (iso)	6.53 (S), 6.79 (R)
2	12 psi He, 100 °C (iso)	4.25 (<i>R</i>), 4.32 (<i>S</i>)
3	20 psi He, 100 °C (iso)	2.34 (<i>R</i>), 2.45 (<i>S</i>)
4	12 psi He, 125 °C (iso)	18.12 (<i>R</i>), 18.60 (<i>S</i>)
6	12 psi H ₂ , 125 °C (iso)	3.32 (S), 3.48 (R)
5	12 psi H ₂ , 125 °C (iso)	6.60 (S), 6.92 (R)

Determination of Absolute Configuration

Absolute configurations of the biotransformation products were determined via co-injection with independently synthesized standard material on GC using a chiral stationary phase. Reference material was obtained as follows: Sharpless dihydroxylation of 2-methyl-2,7-octadiene using α -AD-mix¹⁴ gave (*S*)-**4** (ee 87%).

Diol (*R*)-1 was synthesized based on a procedure previously described:⁸ Oxidation of *rac*-1 (50 mg, 0.30 mmol) with pyridinium-SO₃ complex (150 mg, 0.94 mmol) in anhyd DMSO (3 mL) yielded 2-methyl-6-methylene-2-hydroxy-oct-7-en-3-one (30 mg, 61%).

 R_f (PE-EtOAc, 5:1) = 0.59 (detection I).

¹H NMR (500.13 MHz, $CDCl_3$): $\delta = 5.01$ (s, 1 H), 5.06 (s, 1 H), 5.11 (d, 1 H, J = 10.8 Hz), 5.29 (d, 1 H, J = 17.6 Hz), 6.38 (dd, 1 H, J = 17.6, 10.9 Hz).

 ^{13}C NMR (125.76 MHz, CDCl₃): δ = 25.43, 26.51, 29.74, 34.45, 76.23, 113.72, 116.47, 138.30, 144.92, 213.77.

The latter material was reduced with Baker's yeast to furnish (R)-1 (ee 93%, yield 20%).

Screening of Biocatalysts for the Hydrolysis of 4 and 5; General Procedure

rac-Epoxides **1a**, **2a** and **3a** (5 μ L) were hydrolyzed using rehydrated lyophilized cells (50 mg) in Tris-buffer (1 mL, 0.05 M, pH 8.0) by shaking the mixture at 30° C with 130 rpm. After 24 h and 48 h, aliquots of these solutions (0.5 mL) were extracted twice with EtOAc (0.5 mL each). To facilitate phase separation, the cells were removed by centrifugation. The combined organic layers were dried and analyzed by GC on a chiral stationary phase.

Acknowledgement

This work was performed within the Spezialforschungsbereich Biokatalyse (SFB-A4, project no. F-104) and was financed by the Fonds zur Förderung der wissenschaflichen Forschung and the Austrian Ministry of Science (Vienna).

References and Notes

- (1) Orru, R. V. A.; Faber, K. *Curr. Opinion Chem. Biol.* **1999**, *3*, 16.
- (2) Kroutil, W.; Mischitz, M.; Faber, K. J. Chem. Soc., Perkin Trans. 1 1997, 3629.
- (3) Steinreiber, A.; Mayer, S. F.; Saf, R.; Faber, K. Tetrahedron: Asymmetry 2001, 12, 1519.
- (4) Steinreiber, A.; Osprian, I.; Mayer, S. F.; Orru, R. V. A.; Faber, K. *Eur. J. Org. Chem.* **2000**, 3703.
- (5) Osprian, I.; Stampfer, W.; Faber, K. J. Chem. Soc., Perkin Trans. 1 2000, 3779.
- (6) Bohlmann, F.; Ahmed, M.; King, R. M.; Robinson, H. Phytochemistry 1983, 22, 1281.
- (7) Barrero, A. F.; Sanchez, J. F.; Altarejos, J.; Zafra, M. J. *Phytochemistry* **1992**, *31*, 1727.
- (8) Hioki, H.; Ooi, H.; Mimura, Y.; Yoshio, S.; Kodama, M. Synlett 1998, 729.
- (9) Tressl, R.; Friese, L.; Fendesack, F.; Köppler, H. J. Agric. Food Chem. 1978, 26, 1422.
- (10) Naya, Y.; Kotake, M. Tetrahedron Lett. 1967, 26, 2459.
- (11) (a) Masaki, Y.; Nagata, K.; Serizawa, Y.; Kaji, K. Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 1983, 26, 545.
 (b) Chem. Abstr. 1983, 101, 23162x.
- (12) Ibrahim, N.; Eggimann, T.; Dixon, E. A.; Wieser, H. *Tetrahedron* **1990**, *46*, 1503.
- (13) Curran, D. P.; Heffner, T. A. J. Org. Chem. 1990, 55, 4585.
- (14) Crispino, G. A.; Sharpless, K. B. Synlett 1993, 47.

- (15) Since the biocatalytic hydrolysis of trisubstituted epoxides could proceed in an enantioconvergent fashion (not via kinetic resolution), the general use of E-values for the description of enantioselectivities is inapplicable.
 (16) Helleteim H : Steinscher A : Mayor S E : Eabor K
- (16) Hellström, H.; Steinreiber, A.; Mayer, S. F.; Faber, K. *Biotechnol. Lett.* 2001, 23, 169.
- (17) Yamada, S.; Oh-hashi, N.; Achiwa, K. *Tetrahedron Lett.* 1976, 29, 2557.
- (18) Yamada, S.; Oh-hashi, N.; Achiwa, K. Tetrahedron Lett. 1976, 29, 2561.
- (19) Kamber, M.; Pfander, H. Helv. Chim. Acta 1984, 67, 968.
- (20) In contrast, mesylation proceeded very slowly.
- (21) Nielsen, B. E.; Lemmich, J. Acta Chem. Scand. **1969**, 23, 962.

- (22) Mischitz, M.; Kroutil, W.; Wandel, U.; Faber, K. *Tetrahedron: Asymmetry* **1995**, *6*, 1261.
- (23) Kroutil, W.; Osprian, I.; Mischitz, M.; Faber, K. Synthesis 1997, 156.
- (24) Osprian, I.; Kroutil, W.; Mischitz, M.; Faber, K. *Tetrahedron: Asymmetry* **1997**, *8*, 65.
- (25) Krenn, W.; Osprian, I.; Kroutil, W.; Braunegg, G.; Faber, K. *Biotechnol. Lett.* **1999**, *21*, 687.
- (26) Morizawa, Y.; Kanakura, A.; Yamamoto, H. Bull. Chem. Soc. Jpn. 1984, 57, 1935.
- (27) Vliet, M. C. A.; Arends, I. W. C. E.; Sheldon, R. A. Synlett 2001, 248.
- (28) Fournier-Nguefack, C.; Lhoste, P.; Sinou, D. *Tetrahedron* **1997**, *53*, 4353.